دورية أكاديمية

Minimal acute toxicity from proton beam therapy for major salivary gland cancer.

التفاصيل البيبلوغرافية
العنوان: Minimal acute toxicity from proton beam therapy for major salivary gland cancer.
المؤلفون: Chuong, Michael, Bryant, John, Hartsell, William, Larson, Gary, Badiyan, Shahed, Laramore, George E., Katz, Sanford, Tsai, Henry, Vargas, Carlos
المصدر: Acta Oncologica; Feb2020, Vol. 59 Issue 2, p196-200, 5p, 1 Diagram, 3 Charts
مصطلحات موضوعية: NAUSEA -- Risk factors, DEGLUTITION disorders, INTERPROFESSIONAL relations, PAROTID gland tumors, POSTOPERATIVE period, RADIATION doses, RADIATION dosimetry, RADIATION injuries, RISK assessment, SALIVARY gland tumors, SUBMANDIBULAR gland, TASTE disorders, TREATMENT effectiveness, DISEASE incidence, XEROSTOMIA, PROTON therapy, MUCOSITIS, DISEASE risk factors
مصطلحات جغرافية: UNITED States
مستخلص: Introduction: Proton beam therapy (PBT) reduces normal organ dose compared to intensity-modulated radiation therapy (IMRT) for patients with major salivary gland tumors. It is not known whether this dosimetric advantage is clinically meaningful for reducing acute toxicity. Methods: We evaluated treatment parameters and acute toxicity outcomes of patients with major salivary gland cancers enrolled on the Proton Collaborative Group REG001-09 trial (NCT01255748). Results: One-hundred and five patients with a median age of 61 years were included. The majority had parotid (N = 90) versus submandibular gland (N = 15) tumors. The patients were treated across seven institutions in the United States between 2010 and 2017, most commonly in the postoperative setting (70.5%) although a minority were treated definitively (29.5%). Median PBT dose was 66.5 GyE in 33 fractions; only one patient was prescribed less than 50 GyE. Chemotherapy was given concurrently to 20%. Median follow-up was 14.3 months. Acute grade 2 or higher toxicity included nausea (1.5%), dysgeusia (4.8%), xerostomia (7.6%), mucositis (10.5%) and dysphagia (10.5%). Conclusions: PBT should be strongly considered when ipsilateral radiation therapy is indicated for major salivary gland cancer based on a considerably lower incidence of acute grade 2 or higher toxicity in this analysis compared to historical IMRT outcomes. [ABSTRACT FROM AUTHOR]
Copyright of Acta Oncologica is the property of Medical Journals Sweden AB and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:0284186X
DOI:10.1080/0284186X.2019.1698764